Arnout Schepers
CEO TenAces Biosciences
Arnout Schepers is CEO of TenAces Biosciences, with over 15 years of experience in both academia and the biotech industry. He is dedicated to use his background in molecular biology, tissue engineering, and cell therapy to develop therapeutic applications that can address unmet medical needs. Before founding TenAces Biosciences, he served as Director of Research at CellPoint, where he led the development of innovative CAR T-cell therapies. Prior to that, he had several positions at top research institutions and co-founded a company for the valorisation of scientific images. Together with his team at TenAces Biosciences, he is currently developing a computational framework aimed at enabling the rational design of molecular glue therapeutics.
Seminars
When starting molecular glue development from scratch, finding the right interaction to stabilize is the most crucial
step. In this workshop, you will learn to decode targetligase pairs and accurately visualize ternary complexes to accelerate molecular glue discovery. We will cover:
- How to identify the right target-ligase pairings with high-throughput assays
- Choosing the best libraries, assays, and biophysical methods to discover and validate hits for molecular glue development
- Using in silico modeling to optimize ternary complex visualization
- What criteria and validation strategies should be used to determine whether a novel E3 ligase is suitable for therapeutic development?
- In what ways do novel ligases offer functional or pharmacological advantages over traditional ligases like CRBN or VHL?
- How can we build a compelling case—biologically and commercially—for prioritizing a novel ligase over established workhorses in drug development pipelines?
